Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the association of rheumatologists of Russia
E. L. Nasonov,A. M. Lila,Vadim I. Mazurov,B. S. Belov,A. E. Karateev,Tatiana Dubinina,O. A. Nikitinskaya,A. A. Baranov,Diana Abdulganieva,S. V. Moiseev,A. I. Zagrebneva +10 more
- Vol. 59, Iss: 3, pp 239-254
Reads0
Chats0
TLDR
The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.Citations
More filters
Journal ArticleDOI
Деплеция в-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (covid-19)
Е. Л. Насонов,А. С. Авдеева +1 more
TL;DR: According to the recommendations of the Association of Rheumatologists of Russia, a more rigorous assessment of indications for induction and maintenance therapy of RTX therapy and harmonization of the timing of drug administration and vaccination is required.
Journal ArticleDOI
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
TL;DR: The frequency of exacerbation of RD after vaccination against COVID-19 seems to be quite low (5–7%) and has no significant associations with a specific vaccine or anti-rheumatic therapy, and unambiguous interpretation is difficult.
Journal ArticleDOI
Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
Evgeny Nasonov,T.V. Korotaeva +1 more
TL;DR: The current achievements, trends and recommendations regarding the use of JAK inhibitors in the treatment of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.
Journal ArticleDOI
Rheumatoid arthritis and post-COVID-19 syndrome
TL;DR: It is thought that SARS-CoV-2 infection may be a trigger factor for new rheumatic musculoskeletal diseases, including rheumatoid arthritis or COVID-19 can unmask previously undetected RA, and arthritis in the post covid period may induce problems in differential diagnosis of rhematic diseases.
Journal ArticleDOI
Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)
TL;DR: Preliminary data suggest that vaccination against COVID-19 in patients with IRD appears to be quite safe, and further studies are needed to investigate the safety, immunogenicity, and clinical efficacy of CO VID-19 immunization in rheumatic patients.
References
More filters
Journal ArticleDOI
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.
Christopher T Rentsch,Nicholas J DeVito,Brian MacKenna,Caroline E Morton,Krishnan Bhaskaran,Jeremy P Brown,Anna Schultze,William J Hulme,Richard Croker,Alex J Walker,Elizabeth A. Williamson,Christopher M. Bates,Seb Bacon,Amir Mehrkar,Helen J Curtis,David M. Evans,Kevin Wing,Peter Inglesby,Rohini Mathur,Henry Drysdale,Angel Y S Wong,Helen Mcdonald,Jonathan Cockburn,Harriet Forbes,John Parry,Frank Hester,Sam Harper,Liam Smeeth,Ian J. Douglas,William G Dixon,Stephen J. W. Evans,Laurie A. Tomlinson,Ben Goldacre +32 more
TL;DR: It is found that completion of randomised trials investigating pre-exposure prophylactic use of hydroxychloroquine for prevention of severe outcomes from COVID-19 are warranted and robust to missing information for additional biologic treatments for rheumatological disease.
Journal ArticleDOI
Perspectives on vaccine induced thrombotic thrombocytopenia.
Arad Dotan,Yehuda Shoenfeld +1 more
TL;DR: In this paper, the authors reported that vaccination with ChAdOx1 nCov-19 (developed by Oxford and AstraZeneca) may result in a vaccine-induced catastrophic thrombosis in atypical sites, along with the production of autoantibody against platelet-factor 4 (PF4).
Journal ArticleDOI
Risk of death among people with rare autoimmune diseases compared with the general population in England during the 2020 COVID-19 pandemic.
Emily Peach,Megan Rutter,Peter Lanyon,Matthew J. Grainge,Richard Hubbard,Jeanette Aston,Mary Bythell,Sarah Stevens,Fiona A Pearce +8 more
TL;DR: The risk of all-cause death is more prominently raised during COVID-19 among people with RAIRD than among the general population, according to a cohort study conducted in Hospital Episode Statistics for England 2003 onwards.
Journal ArticleDOI
Response to 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Shi et al .
TL;DR: In terms of case-controlled study, studies with data regarding the prevalence or clinical outcomes of COVID-19 in patients with autoimmune diseases and patients without ADs or the general population are included.
Journal Article
COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)
Carlo Alberto Scirè,Greta Carrara,Anna Zanetti,Gianpiero Landolfi,Cecilia Beatrice Chighizola,Alessia Alunno,Alessia Alunno,Laura Andreoli,Roberto Caporali,Roberto Gerli,Gian Domenico Sebastiani,Guido Valesini,Luigi Sinigaglia +12 more
TL;DR: Although the report mainly includes the most severe cases, its temporal and spatial trend supports the validity of the national surveillance system and investigates the safety of immunomodulatory treatments.